Combining Paclitaxel, Oxaliplatin, and S-1 for treating advanced gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and safety of a combination therapy using Paclitaxel (albumin-bound), Oxaliplatin, and S-1 for patients with initially unresectable or potentially resectable metastatic gastric adenocarcinoma. The approach aims to convert the disease to a state where surgical intervention may be possible. Participants will undergo treatment and be monitored for their response and any adverse effects. The study focuses on patients who meet specific health criteria and have a confirmed diagnosis of gastric adenocarcinoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age of 18-75 years; male or female.
* Karnofsky Performance Status Score ≥70.
* Histological diagnosis of gastric adenocarcinoma, HER2 expression negative.
* The initial unresectable locally advanced or potentially resectable metastatic gastric adenocarcinoma, potentially resectable factor includes a single liver metastases, localized abdominal para-aortic lymph node (16a1 / b2) metastasis or positive abdominal free cancer cells.
* Physical condition and organ function allow for larger abdominal surgery.
* Subject baseline blood routine and blood biochemistry indexes meet the following criteria: hemoglobin(HB) ≥90 g/L; absolute neutrophil count(ANC) ≥1.5×109 /L; platelet count(PLT) ≥100×109 /L; alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤2.5 x upper limit of normal range (ULN); total bilirubin (TBIL)≤1.5 x upper limit of normal range (ULN); Creatinine(Cr)≤1.5 x upper limit of normal range(ULN); Serum albumin≥30g/L.
* Echocardiographic scan confirmed left ventricular ejection fraction (LVEF) ≥ 50%.
* No serious accompanying disease lead to a survival period of \<5 years.
* Agree and be able to follow the protocol during the study period.
* Written informed consent was provided prior to the study screening and the patient was informed that the study could be withdrawn at any time during the study without any loss.

Exclusion Criteria:

* For the treatment of the gastric cancer, patients who have received cytotoxic chemotherapy, radiotherapy or immunotherapy, except corticosteroids.
* Pregnancy or breastfeeding woman.
* Women of childbearing age who had a positive pregnancy test at baseline or who did not undergo a pregnancy test. Menopausal women must be stopped for at least 12 months to ensure that no pregnancy is possible.
* Men and women who have sex (with fertility probability) are reluctant to contraception during the study.
* Patients with ascites and positive abdominal free cancer cells.
* There are other history of malignant disease in the last 5 years, except for cured skin cancer and cervical carcinoma in situ.
* Those with a history of epilepsy, central nervous system disease, or mental disorder may be judged by the investigator that their clinical severity may hinder the signing of informed consent or affect the patient's oral medication compliance.
* Clinically severe (active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe drug-affected arrhythmias, or there is a history of myocardial infarction in the last 12 months.
* Upper gastrointestinal stagnation or abnormal physiological function or malabsorption syndrome may affect the absorption of S-1.
* It is known to have peripheral neuropathy ≥ NCI CTC AE grade 2. However, only the deep sputum reflex (DTR) disappears and the patient does not have to be excluded.
* Organ transplantation requires immunosuppressive therapy.
* Severe uncontrolled recurrent infections, or other serious uncontrolled concomitant diseases.
* Moderate or severe renal impairment \[creatinine clearance equal to or lower than 50ml/min (calculated according to Cockcroft and Gault equations), or serum creatinine \> upper normal limit (ULN).
* Those suffering from dihydropyrimidine dehydrogenase (DPD) deficiency are known.
* Those who are allergic to taxanes or any research ingredients.
* Those who received research medications or preparations/treatments (ie, participated in other trials) within 4 weeks prior to enrollment.

Where it's running

• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Jiafu ji, MD — Peking University Cancer Hospital & Institute
• Study coordinator: Jiafu ji, MD
• Email: jiafuj@hotmail.com
• Phone: 86-010-88196048

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R

  This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07914764

• Neoadjuvant immunotherapy plus Nab-P-SOX for locally advanced gastric/GEJ cancer

  This phase 2, single-arm study tests a pre-surgery treatment that combines a PD-1/CTLA-4 bispecific antibody with nab-paclitaxel, oxaliplatin, and S-1 in adults with HER2-negative, locally advanced gastric or GEJ cancer.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07867392

• Maintenance therapy in metastatic gastric cancer: a multicenter look from Colombia

  This study reviews medical records of adults with metastatic gastric cancer in Colombia to see how patients fare after starting maintenance therapy following initial chemotherapy.

  Recruiting at 4 sites Fundación Santa Fe de Bogota · Bogotá, Bogota D.C. and 3 other locations · NCT07856212

• AI-powered tumor response assessment after preoperative treatment in stomach and gastroesophageal junction cancer

  Researchers are testing whether an AI tool called DeepTRG can reliably measure how much cancer remains in tissue removed after preoperative therapy in stomach and GEJ cancer, without needing a human to correct the AI results.

  Recruiting Hebei Medical University · Shijiazhuang, None Selected · NCT07849608

• Image-guided platform helps find sentinel lymph nodes in early gastric cancer

  This study tests whether an image-guided platform with a deep learning model can find and retrieve sentinel lymph nodes better than standard palpation in people with early gastric cancer undergoing LECS-SNNS.

  Recruiting Beijing Friendship Hospital · Beijing · NCT07835087

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.